

CURRICULUM VITAE

Arie Szatkowski, M.D.
7362 Southcrest Parkway
Southaven, MS 38671
Phone: (901) 271-1000

WORK EXPERIENCE:

July 2003 – Present

- Stern Cardiovascular Foundation, Southaven, MS 38671
- Medical Director of Cardiovascular Services, Baptist Desoto Hospital
- Quality Director, Stern Cardiovascular Center
- Champion Physician/Director of Congestive Heart Failure Improvement Baptist Desoto Hospital
- Secretary of Medical Leadership Staff Council Baptist Hospital

April 2014 – Present

- CV service line medical director for Baptist Memorial Healthcare Corporation

November 2013 – Present

- Director of Cardiac Rehab
- Representative for Baptist Desoto Hospital and Stern Cardiovascular Foundation for Mississippi Heart Attack Alliance. Focus on optimizing outcomes for people who suffer heart attacks in Mississippi.

March 2013 - Present

- Board of Physician Advisory Council, a conglomerate of physician leaders and hospital administrators focused on improving health care delivery.

March 2012 - Present

- Board of Directors, Select Health Alliance a clinically integrated physician network in the mid south.

February 2012 - Present

- Director of Quality, Stern Cardiovascular Alliance.

January 2012 - Present

- Director of Echocardiography, Baptist Desoto Hospital.

January 2012 – Present

- Chest Pain Medical Directorship

January 2011 - Present

- Director CV service line for Baptist Desoto Hospital. Voted number one Hospital in Mississippi for Heart disease management.

HOSPITAL AFFILIATIONS:

Baptist Memorial Hospital - Memphis
6019 Walnut Grove Road
Memphis, Tennessee 38120
Cardiologist – Active, 7/03 to Present

Baptist Memorial Hospital – Desoto
7601 Southcrest parkway
Southaven, Mississippi 38671
Cardiologist – Active, 11/03 to Present

Saint Francis Hospital
5959 Park Avenue
Memphis, Tennessee 38119
Cardiologist – Consulting, 7/03 to Present

FELLOWSHIP:

6/2000– 6/2003 Cardiology Fellowship
New York Presbyterian Hospital
/ Columbia University, New York, NY

INTERNSHIP / RESIDENCY:

6/1997– 6/2000 Internal Medicine
New York Presbyterian Hospital
/ Columbia University, New York, NY

MEDICAL SCHOOL:

8/1993– 5/1997 Medical Degree, Cornell University Medical College
New York, NY

UNDERGRADUATE SCHOOL:

8/1991– 6/1993 Pre-Medical Courses --
Columbia University School of General Studies,
New York, NY

8/1987 – 6/1991 Bachelor of Arts Degree, major in History
Tulane University, New Orleans, LA

BOARD CERTIFICATION:

2000– 2010 Diplomate, American Board of Internal Medicine – Internal Medicine
2003 – 2013 Diplomate, American Board of Internal Medicine – Cardiovascular Disease

LICENSURE:

Tennessee	MD (issued 2/14/03, Active)
New York	MD (issued 2/19/99, Active)
Mississippi	MD (issued 9/22/2003, Active)

PROFESSIONAL ORGANIZATIONS:

2001 - present	American Medical Political Action Committee
2000 - present	Fellow, American College of Cardiology
1997 - present	American Medical Association
2003 – present	Memphis and Shelby County Medical Society
2003 – present	Tennessee Medical Association
2005 – present	American Society of Echocardiography

COMMITTEES:

Chest Pain/ER to Cath Lab Committee (Baptist Hospital)
Congestive Heart Failure

ORAL PRESENTATIONS:

Women and Heart Disease
Congestive Heart Failure – Novel Therapies
Hypertension – Treatment and Goals
Arrhythmias – Diagnosis and Management

AWARDS and HONORS:

2000 – 2001	Physician of the Year -- New York Presbyterian Hospital Columbia University, New York, NY
1999 – 2000	Arnold P. Gold Award for Excellence in Humanism and Teaching Columbia University College of Physicians and Surgeons, New York, NY
1997	George N. Papanicolaou Fellow in Clinical Anatomy Cornell University Medical College, New York, NY

RESEARCH EXPERIENCE:

Arise - Aggressive Reduction of Inflammation Stops Events (sub-investigator)

Atmosphere - "A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV)". Protocol Number: CSPP100F2301 (sub-investigator)

CIRT – Cardiovascular Inflammation reduction Trial (principal investigator)

Destiny –“A 12-Week, Multicenter, Randomized, Double-Blind, 2-Arm Parallel Treatment Regimen, Exploratory Study to Evaluate the Tolerability and Safety of Valsartan Administered Once Daily Versus Twice Daily, in Patients with Stable, Chronic Heart Failure (NYHA Class II-III)”. (sub-investigator)

Ditpa –“A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of DITPA in Patients with NYHA Class III and IV Congestive Heart Failure Who Have Low Serum T₃ Levels (Protocol # DIT-803)”. (sub-investigator)

Emphasis –“THE EFFECT OF EPLERENONE VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALIZATION IN SUBJECTS WITH NYHA CLASS II CHRONIC SYSTOLIC HEART FAILURE”. Study # A6141079 – 1381 (sub-investigator)

RESEARCH EXPERIENCE CONTINUED:

Everest -“Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure”. (sub-investigator)

Focus – “Follow-up Of Clinical Outcomes: The Long-Term AGI1067 plus Usual Care Study”. (sub-investigator)

Jupiter - “A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin (Crestor) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein”. (principal investigator)

Light - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR (sub-investigator)

Pearl - Protocol RLY5016–202: “A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of RLY5016 in Heart Failure Patients”. (sub-investigator)

Poseidon - Biogen Idec Protocol No.: 161HF201: “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral BG9928 in Patients with Heart Failure and Renal Insufficiency”. (IND# 61,944) (sub-investigator)

RED-HF - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia

Precision – “A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing Celecoxib With Naproxen and Ibuprofen”. Protocol no: A3191172 (sub-investigator)

REDUCE-IT - A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA-Intervention Trial) AMR-01-01-0019 (sub-investigator)

Saturn – “A 104 Week, Randomized, Double-Blind, Parallel Group, Multi-Center, Phase IIIB Study Comparing the Effects of Treatment with Rosuvastatin 40mg or Atorvastatin 80mg on Atherosclerotic Disease Burden as Measured by Intravasucular Ultrasound in Patients with Coronary Artery Disease”. D356IC00001 (sub-investigator)

Topcat - Treatment Of Preserved Cardiac function heart failure with an Aldosterone antagonist”. (TOPCAT)

RESEARCH EXPERIENCE CONTINUED:

- 2001 – 2003 Division of Cardiology, Columbia University
Preceptor: Shunichi Homma, M.D.
The Role of Patent Foramen Ovale in the Metastatic Process

- 2001 – 2003 Division of cardiology, Columbia University
Preceptor: Leroy E. Rabbani, M.D.
The Role of Glycoprotein IIB/IIIA Inhibitors on the Hemostatic Profile of Patients Presenting with Unstable Angina

- 1998 – 2000 Division of Circulatory Physiology, Columbia University
Preceptor: Daniel Burkhoff, M.D., Ph.D.
In Vivo Evaluation of a Bone Protein Growth Mixture on Rat Myocardium
In Vivo Evaluation of the effects of an Angiogenic Protein Mixture in the Canine Ischemic Heart
Evaluation of Trans-Myocardial Laser Revascularization Cellular Changes on the Explanted Heart Patients Receiving Left Ventricular Assist Device.

- 1996 – 1997 Department of Hip and Knee Surgery, Hospital for Special Surgery
Sponsor: Thomas Sculco, M.D.
Heterotopic Ossification in Patients with Rheumatoid Arthritis and osteoarthritis Status- Post Arthroplasty.

- 1994 Department of Radiology, Cornell University Medical College
Sponsor: Elias Kazam, M.D.
Diagnosis of Pulmonary Embolism with Spiral computer-Assisted Tomography

- 1991 – 1993 Department of Nuclear Medicine, Mount Sinai School of Medicine
Sponsor: Stanley Goldsmith M.D., Shankar Vallabhajosula, Ph.D.
Non-invasive imaging of Coronary Artery Disease Using Technetium-99m Labeled Peptide.
Assessment of the Biodistribution and Imaging of Technetium-99m Labeled Native LDL

PUBLICATIONS:

REVIEWS:

Szatkowski A, Ndubuka-Irobunda C, Oesterle SN, Burkholl D. Transmyocardial Laser Revascularization. American Journal of Cardiovascular Drugs 2002; 2 : 3.

ABSTRACTS:

Vallabhajosula S, Palestro CJ, Szatkowski A. Technetium-99m Labeled Anti-Granulocyte Antibody: Pharmacokinetics and Radiation Dosimetry. The Journal of Nuclear Medicine 1993; 34.